Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rebecca Gelman

Showing results (11-20 of 57) with videos related to

Pageof 6
Sort By:
Investigational New Drugs|September 14, 2006
Rebeccamycin analog for refractory breast cancer: a randomized phase II trial of dosing schedulesHarold J Burstein, Beth Overmoyer, Rebecca Gelman, et al.
The Breast Journal|January 12, 2008
Incidence of major corrective surgery after post-mastectomy breast reconstruction and radiation therapyJulia S Wong, Alice Y Ho, Carolyn M Kaelin, et al.
International Journal of Radiation Oncology, Biology, Physics|March 2, 2002
Second nonbreast malignancies after conservative surgery and radiation therapy for early-stage breast cancerSharon Galper, Rebecca Gelman, Abram Recht, et al.
Lancet (London, England)|March 16, 2005
Offering participants results of a clinical trial: sharing results of a negative studyAnn H Partridge, Julia S Wong, Katherine Knudsen, et al.
Cancer|June 5, 2003
Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinomaJohanna C Bendell, Susan M Domchek, Harold J Burstein, et al.
Cancer Research|November 4, 2005
HIN-1, an inhibitor of cell growth, invasion, and AKT activationIan Krop, Michele Taylor Parker, Noga Bloushtain-Qimron, et al.
Breast Cancer Research and Treatment|September 25, 2012
Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomicsErica L Mayer, Steven J Isakoff, Giannoula Klement, et al.
Journal of the National Cancer Institute|March 13, 2018
Differences in TP53 Mutation Carrier Phenotypes Emerge From Panel-Based TestingHuma Q Rana, Rebecca Gelman, Holly LaDuca, et al.
Investigational New Drugs|March 9, 2007
Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactionsNancy U Lin, Leroy M Parker, Steven E Come, et al.
International Journal of Radiation Oncology, Biology, Physics|February 6, 2007
Variability among breast radiation oncologists in delineation of the postsurgical lumpectomy cavityDaniel M Landis, Weixiu Luo, Jun Song, et al.
Pageof 6

Showing results (11-20 of 57) with videos related to

Sort By:
Pageof 6
Investigational New Drugs|September 14, 2006
Rebeccamycin analog for refractory breast cancer: a randomized phase II trial of dosing schedulesHarold J Burstein, Beth Overmoyer, Rebecca Gelman, et al.
The Breast Journal|January 12, 2008
Incidence of major corrective surgery after post-mastectomy breast reconstruction and radiation therapyJulia S Wong, Alice Y Ho, Carolyn M Kaelin, et al.
International Journal of Radiation Oncology, Biology, Physics|March 2, 2002
Second nonbreast malignancies after conservative surgery and radiation therapy for early-stage breast cancerSharon Galper, Rebecca Gelman, Abram Recht, et al.
Lancet (London, England)|March 16, 2005
Offering participants results of a clinical trial: sharing results of a negative studyAnn H Partridge, Julia S Wong, Katherine Knudsen, et al.
Cancer|June 5, 2003
Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinomaJohanna C Bendell, Susan M Domchek, Harold J Burstein, et al.
Cancer Research|November 4, 2005
HIN-1, an inhibitor of cell growth, invasion, and AKT activationIan Krop, Michele Taylor Parker, Noga Bloushtain-Qimron, et al.
Breast Cancer Research and Treatment|September 25, 2012
Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomicsErica L Mayer, Steven J Isakoff, Giannoula Klement, et al.
Journal of the National Cancer Institute|March 13, 2018
Differences in TP53 Mutation Carrier Phenotypes Emerge From Panel-Based TestingHuma Q Rana, Rebecca Gelman, Holly LaDuca, et al.
Investigational New Drugs|March 9, 2007
Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactionsNancy U Lin, Leroy M Parker, Steven E Come, et al.
International Journal of Radiation Oncology, Biology, Physics|February 6, 2007
Variability among breast radiation oncologists in delineation of the postsurgical lumpectomy cavityDaniel M Landis, Weixiu Luo, Jun Song, et al.
Pageof 6